APRINOIA Therapeutics

APRINOIA Therapeutics Overview

Founded 2015
Founded
Status Private
Latest Deal Type Accelerator/​Inc
Investors 7

APRINOIA Therapeutics General Information

Description

Provider of clinical research and development services intended to establish a drug discovery and early-stage firm. The company's services focus on treatment of neurodegenerative diseases, enabling its clients to receive drugs required to treat human neurological conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 17F, Number 3, Park Street
  • Taipei, Nangang
  • Taiwan
+886 02 0000 0000

APRINOIA Therapeutics Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

APRINOIA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 27-Jun-2019 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series B) 16-Jan-2018 000.00 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) Completed Clinical Trials - General
1. Seed Round Completed Clinical Trials - General

APRINOIA Therapeutics Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Akelos (Drug Discovery) Angel-Backed New York, NY 0 00000 0000000000 00000
0000000 Venture Capital-Backed San Mateo, CA 00 000.00 00000 00000 000.00
000000000 Venture Capital-Backed New York, NY 000.00 00000000000 000.00
000000000 00000000 Corporation New York, NY 00 000.00 000000000 000.00
000000 000000000 Formerly PE-Backed Germantown, MD 0 000.00 000000000 000.00

APRINOIA Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Ming-Kuei Jang Ph.D Chief Executive Officer & Co-Founder
Kuo-Ju Pan Director, Operations
Paul Tempest Ph.D Senior Vice President, Drug Discovery
Chin-Yin Tai Ph.D Vice President, Neurobiology

1 Former Executive

APRINOIA Therapeutics Board Members (1)

Name Representing Role Since
Kevin Kyung Self Board Member 000 0000

APRINOIA Therapeutics Investors (7)

To view APRINOIA Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0
Company K Partners Venture Capital Minority 000 0000 000000 0
DCI Partners Venture Capital Minority 000 0000 000000 0
IMM Investment Venture Capital Minority 000 0000 000000 0
KTB Network (Seoul) Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial